OLAMIJI ADEPARUSI: Open Payments
NPI 1851772107 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,020 in 172 payments from 13 companies in 2025. Trend: 2023 $3,076 · 2024 $3,703 · 2025 $4,020
Food & beverage: $4,014Education: $6
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $514 |
| Teva Pharmaceuticals USA, Inc. | 28 | $506 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $447 |
| Otsuka America Pharmaceutical, Inc. | 20 | $425 |
| Janssen Pharmaceuticals, Inc | 10 | $371 |
| Vanda Pharmaceuticals Inc. | 12 | $360 |
| Axsome Therapeutics, Inc. | 11 | $254 |
| Lundbeck LLC | 10 | $244 |
| Neurocrine BioSciences, Inc. | 14 | $223 |
| Alkermes, Inc. | 10 | $201 |
Products named: VRAYLAR, CAPLYTA, UZEDY, FANAPT, ABILIFY ASIMTUFII, REXULTI, Auvelity, INGREZZA.
Industry payments across TX — which companies pay providers there.
